AUR-AERW-TTM1-A-1-1-R-A742-41
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.540
- INTERFERON_ALPHA_RESPONSE+0.480
- INTERFERON_GAMMA_RESPONSE+0.480
- OXIDATIVE_PHOSPHORYLATION+0.450
- MYC_TARGETS_V1+0.430
- MTORC1_SIGNALING+0.370
- PANCREAS_BETA_CELLS+0.360
- INFLAMMATORY_RESPONSE+0.350
- E2F_TARGETS+0.300
- IL6_JAK_STAT3_SIGNALING+0.290
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.490
- WNT_BETA_CATENIN_SIGNALING-0.460
- TGF_BETA_SIGNALING-0.370
- UV_RESPONSE_DN-0.340
- MYOGENESIS-0.330
- HYPOXIA-0.310
- MITOTIC_SPINDLE-0.260
- ANGIOGENESIS-0.230
- NOTCH_SIGNALING-0.230
- ESTROGEN_RESPONSE_EARLY-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | a3b44031-71ef-476f-a8bd-3694226ce026 | — | — | 0.880 |
| 2 | TCGA-66-2771-01A-01R-0980-07 | — | cohortSQ1 | 0.872 |
| 3 | SRR29022835 | — | C | 0.870 |
| 4 | SRR8518156 | — | D | 0.857 |
| 5 | TCGA-A2-A0SW-01A-11R-A084-07 | — | C | 0.854 |
| 6 | 2ad90ba0-8038-4bad-afa3-d176f63b42f0 | — | — | 0.852 |
| 7 | TCGA-05-5420-01A-01R-1628-07 | — | cohortA1 | 0.851 |
| 8 | TCGA-A8-A08P-01A-11R-A00Z-07 | — | C | 0.849 |
| 9 | ERR2208906 | — | — | 0.837 |
| 10 | TCGA-E9-A22D-01A-11R-A157-07 | — | D | 0.833 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.540 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.480 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.480 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.450 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.430 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.370 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.360 | Cobimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.350 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.290 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.290 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.280 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.260 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.190 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.190 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.170 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.170 | Idelalisib | — uncovered |